

Dr ZAHRA MADJD, MD PhD

PERSONAL DETAILS

Name: Zahra (Maryam)

Surname: Madjd

Home: 00982122679994

Address: Dep Pathology and Oncopathology Research Centre, Faculty of Medicine,
Tehran University of Medical Sciences, Hemmat Highway, Tehran-Iran, post code:
14496-14535

E-mail: Zahra.madjd@yahoo.com

zmadjd@iums.ac.ir

Academic Attainments and previous appointment

Dates	Description of qualification	Place obtained
1988 -1996	Doctorate in Medicine	Tehran, Iran
1996- 2000	General Practitioner	Tehran, Iran
2000-2001	6 months course in MSc Oncology	University of Nottingham
2001- 2005	PhD , Cancer Immunology	CRUK Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK
2005 - 2006	Post-doctoral Research Fellow (1 year)	University of Nottingham, City Hospital, Dep. Clinical Oncology
2006(contract for 3 years, Left to Iran)	Appointed for Career Development Fellowship, Post doctorate Scientist Supervisor: Professor Sheila Bingham Director: Professor Sir John Walker (Nobel Prize Winner ,1997)	University of Cambridge, Addenbrock's Hospital, MRC, Human Nutrition Unit

Recent Academic Activities

Since Aug 2006	Assistant Professor	Dep Pathology, Faculty of Medicine, Tehran University of Medical Sciences (TUMS)
Since 2007	Core member and research deputy of Oncopathology Research Centre,	Tehran University of Medical Sciences(TUMS)
Since 2007	Core member of Cancer Research Centre	Shahid Beheshti University of Medical Sciences, Shohada tajrish Hospital
Since 2007	Member of Cellular Molecular Research Centre	Tehran university of Medical Sciences
Since Jan 2009	Educational deputy of Dep Molecular Medicine	Tehran University of Medical Sciences,

Details of recent research, employments and activities

- Co-editor of **Iranian Journal of Cancer Prevention (IJCP)**, published (In English) by Cancer Research Centre, Shahid Beheshti University of Medical Sciences (SBMU)
- Member of Research Committee, Dep pathology, TUMS
- Scientific director “**Molecular Basis of Cancer**”seminar, March 2010

Editorial Board of Journal:

- Iranian Journal of Cancer Prevention (IJCP)
- Razi Journal of Medical Sciences (RJMS) (In Farsi)
- Case Reports in Oncological Medicine
- Journal of Solid Tumours

Honours or Prizes

- 1) EACR-18 (European Association of Cancer Research) award, July 2004, Innsbruck, Austria.
- 2) BACR (British Association of Cancer Research) award , ECCO13 meeting, October 2005, Paris
- 3) BACR award at the EACR 20, July 2008, Lyon, France
- 4) Young Researcher award, Iranian Ministry of Health and Education, December 2008

Memberships

1. BACR (British Association for Cancer Research)
2. EACR (European Association for Cancer Research)

Research Activities:

1. Set up of **Tissue Microarray** for the first time in Iran, in Dep Pathology and Oncopathology Research Centre, Tehran University of Medical Sciences
2. Set up of Immunohistochemistry lab, Department of Pathology, Tehran University of Medical Sciences

Research Interests:

- 1) Translational Cancer Research
- 2) Cancer Stem cells
- 3) Biomarkers of solid tumours
- 4) Targeted therapy of Cancer Stem cells

Ongoing Projects:

- 1) The role of Bcl 2 as biomarker of apoptosis resistance and its relation with marker of breast cancer stem Cells (CD44) and ER/PR in human
- 2) Expression of human embryonic stem cell genes *OCT4*, *NANOG* in breast, colorectal, brain and thyroid carcinoma compared to testicular carcinoma.
- 3) Correlation of markers of breast cancer stem cells (CD44 and CD24) with clinicopathological parameters and patients survival (Joint project with Cancer Research Centre, Shahid Beheshti Medical University)
- 4) Analysis of EMSY protein expression in primary breast tumors and its prognostic significance: study of 300 specimens included in tissue microarray (Joint project with Cancer Research Centre, Shahid Beheshti Medical University)
- 5) Expression of Cancer stem marker (CD133) in paediatric solid tumours and its correlation with pathologic parameters in Aliasghar hospital, a study using Tissue microarray
- 6) Expression of cancer stem cell markers in skin tumours (Melanoma, BCCand SCC) and its correlation with pathologic parameters shohada hospital , a study using Tissue microarray, ongoing
- 7) Expression and prognostic significance of cancer stem cell marker (CD133) in lung cancers using TMA, ongoing

Supervision of PhD/ MSc / resident (SpR) projects

1. Gene expression and protein detection of cancer stem cells of Melanoma, skin squamous cell and basal cell carcinoma compared to non-tumorigenic cells using cDNA microarrays and tissue microarrays (supervisor, PhD of Molecular Medicine, Tehran University of Medical sciences)
2. Comparison of gene expression and protein detection of cancer stem cells (Tumorigenic) with non-tumorigenic lung cancer cells (supervisor, PhD of Molecular Medicine, Tehran University of Medical sciences)
3. Molecular imaging of prostate cancer by magnetic nanoprobe conjugated anti-PSCA antibody and assessment of PSCA expression in prostate cancer tissues (supervisor, PhD of Molecular Medicine, Tehran University of Medical sciences)
4. Methylation of promoter gene MGMT (O⁶-methyl guanine methyl transferase) in Atypical Meningioma compared to Grade I, II and III tumours (supervisor MSc of Genetic, Islamic Azad University)
5. Expression of BRCA₁ protein and its relation with markers of breast cancer stem cells (CD44) and prognostic factors in breast cancer patients of Firozgar and Milad hospital between 1385-1386 (Supervisor, resident (SpR) of Pathology, TUMS)
6. Immunohistochemical assessment of ALDH1 enzyme activity as a functional marker of stem cells and precursor cells of breast cancer in patients referring to Rasool-Akram and Milad hospitals between years 1385-1386 (Supervisor, resident (SpR) of Pathology, TUMS)

Advisor of PhD/ MSc / resident (SpR) projects:

7. Targeting extracellular domain of NGEF using polyclonal antibody in prostate cancer (advisor, PhD of Immunology), Tehran University of Medical sciences (TUMS)
8. Molecular study of effect of siRNA on expression and function of BCRP and the role of PI3K/AKT pathway in reducing drug resistance to Mitoxantron in stem cell and non stem cells of breast and colorectal cancer cell lines (MCF7, HT29) (advisor, PhD Dissertation, Molecular Medicine, Tehran University of Medical sciences (TUMS))
9. Investigation of abuse of Ritalin on medial frontal cortex of male rat (advisor, PhD of Physiology), Tehran University of Medical sciences (TUMS)
10. The effect of Apelin-13 on brain damage, brain edema and neurologic disorders in ischemic model of brain infarction of male rat (advisor, PhD of Physiology), Tehran University of Medical sciences (TUMS)

11. Studying the Co-administration of GCSF and Mesenchymal stem cell in STZ-induced diabetes in rat (advisor, PhD of Pharmacology), Tehran University of Medical sciences (TUMS)
12. Immunohistochemical expression of C-MET in Gastric Adenoma carcinomas in patients referring to Rasool- Akram and Firozgar hospitals between years 1387-1388 using Tissue Microarray (advisor, resident (SpR) of Pathology, TUMS)
13. Determination of MGMT promoter hypermethylation in meningioma grade 1,2,3 using tissue microarray (advisor, resident (SpR) of Pathology, Shahid Beheshti University of Medical sciences)
14. Clinicopathologic features of meningioma in correlation with ER, PR, Ki₆₇, P₅₃ and Her₂/neu, using tissue microarray (TMA)
15. Clinicopathologic features of Craniopharyngioma in correlation with TMA of ER, PR, Ki₆₇, P₅₃ and Her₂/neu
16. The neuroprotective effects of melatonin on the nerve toxicity caused by beta amyloid and NF-kB of the rat model (advisor, PhD of Neurosciences)
17. Study of the neuroprotective effects of exogenous melatonin on the dopaminergic neurons of the substantia nigra of the rat menopausal model (advisor, MSC of Anatomy)
18. Expression of isoform of enos in testis of obstructive azoospermia compared to non-obstructive azoospermia male (advisor, MSc of Anatomy, Shahid Beheshti Medical University)

PUBLICATIONS

Published papers

1. Loss of CD59 expression in breast tumours correlates with poor survival. **Madjd Z**, Pinder S E, Paish C, Ellis IO, Carmichael J, Durrant L G. *J Pathology* (2007 IF: **5.423**) , 2003, 200: 633-639.
2. Loss of CD55 is associated with aggressive breast tumours. **Madjd Z**, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. *Clinical Cancer Research* (2007 IF: **6.25**), 2004, 10: 2797-2803
3. Do poor prognosis breast tumours express membrane cofactor proteins (CD46)? **Madjd Z**, Durrant LG, Pinder SE, Ellis IO, Ronan J, Rushmere NK and Spendlove. *Cancer Immunology Immunotherapy* (2007 IF: **3.728**), 2005 Feb;54(2):149-56
4. Total loss of MHC class I molecules is an independent indicator of good prognosis in breast cancers. **Madjd Z**, Pinder SE, Spendlove I, Ellis IO, and Durrant LG. *International J Cancer* (2007 IF: **4.555**) . 2005 Nov 1; 117(2): 248-55.
5. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC Class I expression correlates with a poor prognosis in early stage patients. Watson NFS, Ramage J, **Madjd Z**, Spendlove I, Ellis IO, Scholefield J, Durrant LG. *Int J Cancer* (2007 IF: **4.555**) . 2006 Jan 1; 118(1): 6-10.
6. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. Watson NFS, **Madjd Z**, Ellis IO, Scholefield J, Spendlove I. Durrant LG. *World J Surg Oncology* (2007 IF: **1.778**). 2005 Jul 19; 3:47.
7. Expression of the Membrane Complement Regulatory Protein CD59 (Protectin) is Associated with Reduced Survival in Colorectal Cancer patients. Watson NFS, Durrant LG, **Madjd Z**, Ellis IO, Scholefield J, and Spendlove I. *Cancer Immunology Immunotherapy* (2007 IF: **3.728**) . 2005 Sep 3;1-8
8. Over-expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. **Madjd Z**, Parsons T, Watson NFS, Spendlove I, Ellis IO and Durrant LG. *Breast Cancer Research*. (2007 IF: **4.371**); 7(5):R780-7. 2005 Jul 28.
9. Expression of the stress related protein MICA is an independent indicator of good prognosis in colorectal cancer patients. Watson NFS, Spendlove I, **Madjd Z**, Moss R, Green A, Ellis IO, Durrant LG, Scholefield JH. *International J Cancer* (2007 IF: **4.555**). 2006 Mar 15; 118(6):1445-52.

10. Cytoplasmic expression p27^{KIP-1} is associated with a favourable prognosis in colorectal cancer patients. NFS Watson, LG Durrant, JH Scholefield, **Z Madjd**, D Scrimgeour, I Spendlove, IO Ellis, PM Patel. World J Gastroenterology. 2006Oct 21;12(39).
11. The p53 Positive Bcl-2 Negative Phenotype is an independent marker of prognosis in breast cancer. Phil Rolland, Ian Spendlove, **Zahra Madjd**, Emad A Rakha, Patel Poulam, Ian O. Ellis, Lindy Durrant. International J Cancer (2007 IF: **4.555**), 22 Dec 2006 .
12. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Rolland P, **Madjd Z**, Durrant L, Ellis IO, Layfield R, Spendlove I. Endocrine Related Cancer(2007 IF: 5.193). 2007 Mar;14(1):73-80.
13. Up-regulation of MICA on high-grade breast carcinomas. **Madjd Z**, Pinder SE, Spendlove I, Watson NFS, Moss R, Bevan S, Durrant LG. Cancer immunity, Oct 2007
14. The need for palliative care services in Iran; an introductory commentary. Asadi-Lari M, **Madjd Z**, Akbari ME. Iranian Journal of Cancer Prevention. Vol.1, No1, 1-5, .2008. Jan
15. Spiritual care at the end of life in the Islamic context, a systematic review, Asadi-Lari M, **Madjd Z**, Gooshegir. Iranian Journal of Cancer Prevention. Vol.1, No 2, July 2008.
16. Gaps in the provision of spiritual care for terminally ill patients in Islamic societies, a systematic review. Mohsen Asadi-Lari, **Zahra Madjd**, Sayyed Ashrafeddin Goushegir. Advances in Palliative Medicine 2008, 73–80.
17. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours.**Madjd Z**, Zare Mehrjerdi A, Sharifi A , Molanaei S, Zohourian S, Asadi Lari M. Cancer Immunity. April 2009.vol9.p4.
18. The Concept of Palliative Care Practice among Iranian General Practitioners. Asadi-Lari M, **Madjd Z**, Afkari ME, Goushegir A, Baradaran HR. . Iranian Journal of Cancer Prevention. Vol.2, No 3, summer 2009.
19. OCT4, an embryonic stem cell marker, is expressed in breast, brain and thyroid carcinomas compared to testicular carcinoma. **Madjd Z**, Hashemi F, Shayanfar N, Farahani E , Zarnani AH, Sharifi AM. Iranian Journal of Cancer Prevention. Vol.2, No 4, autum 2009.
20. Occult Hepatitis C Virus Infection in Iranian Patients with Chronic Liver Disease with Unknown Etiology, Farah Bokharaei Salim, Hossein keyvani, Seyed Moayed Alavian, Seyed Hamid Reza Monavari **Zahra Madjd**, Mohsen Nasiri Tousi, Amir Houshang Alizadeh' Journal of Medical Virology, 2011, June (IF=2.5).

21. Neuroprotective Effect of Exogenous Melatonin on Dopaminergic Neurons of the Substantia Nigra in Ovariectomized Rats. Fereshteh Mehraein, Reza Talebi, Behnamedin Jameie, Mohammad Taghi Joghataie and **Zahra Madjd**, Iranian Biomedical Journal 15 (1 & 2): 44-50 (April & January 2011).
22. BRCA1 protein expression level and CD44+ phenotype in breast cancer patients. **Zahra Madjd**, Adel Karimi, Saadat Molanae, Mohsen Asadi-Lari. CELL JOURNAL (Yakhteh), Vol 13, No 3, Autumn 2011.
23. Immunohistochemical localization of endothelial nitric oxide synthase in testicular cells of men with non- obstructive azospermia, Khadijeh Foghi , Marefat Ghaffari Novin., **Zahra Madjd Jabbari**, Tohid Najafi., Mohammad Hasan Heidari., Abouzar Rostampour Yasoori. Iranian Journal of Reproductive Medicine Vol.9. No.4. pp:277-280, Autumn 2011.
24. Do clinical and demographic features of patients with upper-gastrointestinal cancer affect their health-related quality of life? Ali Esmaili-Hesari, Fatemeh Homai, Abbas Motevallian, **Zahra Madjd**, Masoud Solaymani-Dodaran, Mohsen Asadi-Lari. International Journal of Preventive Medicine, Autumn 2011.
25. Inequalities in cancer distribution in Tehran, a disaggregated estimation of 2007 incidence by 22 districts. Marzieh Rohani-Rasaf, Rashid Ramezani, Mohammad-Reza Rohani-Rasaf, Mitra Mehrazma, **Zahra Madjd**, Reza Entezarmahdi, Mohsen Asadi-Lari International Journal of Preventive Medicine, Autumn 2011.
26. High expression of stem cell marker ALDH1 is associated with mutated BRCA1 in invasive breast carcinomas, Zahra Madjd, Babak Ramezani , Maryam Kadivar, Mohsen Asadi Lari, Saadat Molanae, Cell Journal (yakhteh), submitted, 2011.
27. Expression of stem cell markers, CD133 and CD44 in pediatric solid tumours, a study using Tissue microarray. **Zahra Madjd** , Mitra Mehrazma , Elham Kalantari, Mahshid Panahi, Alireza Hendi , WJP, submitted, 2011.

Papers in Persian:

1. Expression of BRCA1 Protein in Invasive and In Situ Carcinomas and its Relation with Marker of Breast Cancer Stem Cells (CD44) and Prognostic Factors in Breast Cancer Patients. **Madjd Z**, Karimi A, Hashemi F, Molanae S, Razi Journal of Medical Sciences Vol. 17, No. 80 & 81, Feb/Mar 2010-2011
2. The immunohistochemical assessment of ALDH1 activity in breast cancer and it's correlation with pathologic features. Babak Ramezani, Zahra Madjd, Maryam Kadivar, Saadat Molanae. Tehran University Medical Journal; Vol. 69, No. 9, December 2011: 529-536

Book:

1. Cancer and Immune system in "**Iran Cancer Report**", in Farsi, 2008, By Cancer Research Centre, Shahid Beheshti University of Medical Sciences
2. **Tissue Microarrays, Evolutionary in Pathology Research**, in Farsi, 2009, By Oncopathology Research Centre, IUMS
3. **What we should know about Breast Cancer**, hundreds questions and answers about Breast cancer , in Farsi, 2010, Oncopathology Research Centre, IUMS
4. **Complement Regulatory Proteins in Breast Cancer**, Madjd Z and Durrant LG In English, 2010, ISBN (978-3-8383-3769-2), published by LAP LAMBERT Academic Publishing AG & Co. KG, Germany, Distribution by Amazon.
www.amazon.com

ABSTRACTS AND CONFERENCE PROCEEDINGS

1. **Madjd Z**, Asadi-Lari M, Azizi F. Characteristics of thyroid disorders before and after iodized salt consumption. Proceeding of 4th International Congress on Endocrine Disorders, Nov 1996
2. **Madjd Z**, Pinder S, Ellis I O, Carmichael J, Durrant LG. CD59 and CD55 as independent indicator of poor prognosis in breast cancer patients. **British J of Cancer. 86, 2002.**
3. **Madjd Z**, Spendlove I, Pinder SE, Moss R, Bradley R, Durrant L. Expression of complement regulatory proteins CD55 and CD59 on breast cancer. **Clinical Cancer Research, 2003 proceeding of the AACR.**
4. **Madjd Z**, Pinder SE, Spendlove I, and Durrant LG. Expression of CD55 (Decay Accelerating Factor) in breast carcinomas and its prognostic significance. **Immunology Letters. 2003, 87, P:208** (Abstracts of the 15th European Immunology Congress (EFIS 2003).
5. **Madjd Z**, Pinder SE, Spendlove I and Durrant LG. Unexpectedly loss of CD55 and CD59 is associated with aggressive breast tumours. **FASEB Journal, Vol.17, Issue 7, 2003.** (2003 Proceeding of the AAI).
6. **Madjd Z**, Pinder SE, Spendlove I, Durrant LG. Prognostic value of complement regulatory proteins CD55 and CD59 in breast cancer. **British J Cancer. Supplement July, 2003.**
7. **Madjd Z**, Pinder SE, Spendlove I, Durrant LG. Which complement regulatory proteins could be a good target for a breast cancer vaccine? **European J Cancer. Vol 1 No 5, Sep 2003.**
8. **Madjd Z**, Bevin S, Spendlove I, Moss R, Durrant LG. Expression of MHC class I-related molecule MICA in breast carcinomas and its prognostic significance. **Immunology. Supplement. December 2003.**

9. **Madjd Z**, Spendlove I, Pinder SE, Rushmere NK, Morgan BP and Lindy G Durrant. Expression of membrane cofactor protein (CD46) on breast tumours. **Clinical Cancer Research, 2004 proceeding of the AACR.**
10. **Madjd Z**, Pinder SE, Spendlove I, Moss R, Bevin S, Durrant LG. Up-regulation of stress inducible MICA on high-grade breast carcinomas. **Supplement Cancer Detection and Prevention Strategy, Jan 2004.**
11. **Madjd Z**, Pinder S E, Spendlove I, Ellis I O, and Durrant L G. Unexpected up regulation of MHC class I molecules in poor prognosis breast cancer. **British J Cancer. Supplement June 2004.** [presented orally in BCRM, 2004, Manchester]
12. **Madjd Z**, Pinder S E, Ian Spendlove, John Ronan and Lindy G Durrant. Loss of MHC class I molecules in breast tumours results in susceptibility to natural killer cell activation. **European J Cancer, Supplement, July 2004.**
13. **Madjd Z**, Pinder S E, Spendlove I, Ellis I O, and Durrant LG. Loss of HLA class I is associated with good prognosis in breast cancer patients. **Proceeding of BIR, Nov 2004.** [presented orally in Prognostic Testing in Cancer, BIR, London, Nov 2004]
14. **Madjd Z**, Pinder S E, Spendlove I, Ellis I O, and Durrant LG. Loss of MHC Class I is an independent indicator of good prognosis in breast Cancer. **Proceeding of AACR, 2005.**
15. **Madjd Z**, Spendlove I, Ellis IO, Parsons T, and Durrant LG. Prognostic significance of SC101, a monoclonal Antibody against Lewis^{y/b} in breast tumours. **Proceeding of AACR, 2005.**
16. **Madjd Z**, Pinder S E, Spendlove I, Ellis IO, and Durrant LG. Prognostic significance of membrane cofactor protein (CD46) on breast tumours. **Immunology 2004, 113 (S1), British Society for Immunology, Harrogate 2004 .**
17. Watson NFS, Scholefield J, **Madjd Z**, Green A, Moss R, Spendlove, Ellis IO, Durrant LG. Prognostic value of MICA expression in colorectal carcinoma. **Immunology 2004; 113: (s1) late supplement. British Society for Immunology, Harrogate 2004 .**
18. NFS Watson, JH Scholefield, **Z Madjd**, A Green, R Moss, I Spendlove, IO Ellis and LG Durrant. Prognostic value of MICA expression in colorectal carcinoma. The Ninety-Ninth Annual General Meeting of the Physicians of Great Britain and Ireland, **Nottingham, April 2005 .**
19. NFS Watson, I Spendlove, **Z Madjd**, R Moss, A Green, IO Ellis, LG Durrant, JH Scholefield. The prognostic significance of MICA expression in colorectal cancer: An immunohistochemical study using prognostic tissue microarrays. The association of coloproctology of Great Britain and Ireland, The Royal Dublin Society, **5-7 July 2005 (oral).**
20. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson Ian Spendlove, Ian Ellis and Lindy G Durrant. High expression of SC101 antibody is associated with decreased survival in lymph node negative carcinomas. ncri. October 2005. Birmingham
21. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson Ian Spendlove, Ian Ellis and Lindy G Durrant Stat1 expression is an independent indicator of prognosis in lymph node positive carcinomas. ncri. October 2005. Birmingham
22. **Zahra Madjd**, Ahmad Al-Attar, Nicholas FS Watson Ian Spendlove, Ian Ellis and Lindy G Durrant. Prognostic significant of IFN γ receptor (IFNGR1) in breast carcinomas. ECCO 13. Paris NOV 2005

23. Ahmad Al-Attar, **Zahra Madjd**, Nicholas FS Watson, Ian Spendlove, Duncan Scrimgeour, Ian Ellis and Lindy G Durrant. Co-expression of P27 kip1/p21 is an independent indicator of good prognosis in lymph node positive breast carcinomas. ECCO13. Paris NOV 2005
24. NFS Watson, **Z Madjd**, D Scrimgeour, A Al-Attar, I Spendlove, IO Ellis, JH Scholefield and LG Durrant Cytoplasmic p27^{KIP-1} expression is an indicator of good prognosis in colorectal carcinomas. ECCO13. Paris NOV 2005
25. NFS Watson, R Moss, **Z Madjd**, I Spendlove, JH Scholefield and LG Durrant. Prognostic impact of Stat1 expression in colorectal cancer patients. **Immunology** 2005, British Society for Immunology, Harrogate, Dec 2005
26. **Madjd Z**, Hashemi F, Kadivar M, Rakhshani N, Asadi Lari. Prevalence of cancer stem cells and its association with ER, PR and Erb2 in breast cancer patients. European Conference on Cancer and Ageing Warsaw, Poland, October 4-6, 2007
27. **Madjd Z**, Zare Mehrjerdi A, Sharifi A, Molanaei S, Zohoorian S, Sadeghipour A, Asadi Lari M. **Can breast cancer stem cells resist apoptosis through the regulation of Bcl2? An immunohistochemistry study of 200 breast tumours. Iranian Congress of Pathology. Nov 2007.**
28. **Madjd Z**, Durrant LG, and Pinder SE. Can complement regulatory proteins use as a target for cancer vaccine in breast cancer patients? APCC, Dec 2007.

Lectures and Oral presentations in this period (since Sep 2006):

1. International Royan Congress, Sep 2006, Tehran
2. Second Congress of Breast, 9-10 Nov, Tehran
3. 8th Congress of Iranian Society of Pathology, 2-4 Nov 2006, Tehran
4. CD59 as an independent indicator of poor prognosis in breast carcinomas, a tissue microarray study of 520 patients, presented in 8th Congress of Iranian Society of Pathology, 2-4 Nov 2006, Tehran
5. Breast Cancer congress, Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Feb 2007.
6. Lectures in Pathology CME, Iran University of Medical Sciences, May 2007
7. Expression of Glycolipid Monoclonal Antibody, SC104, improved survival in colorectal cancer patients, A tissue microarray study. Madjd Z, Watson NF, Ellis IO, Durrant LG. The 9th annual Congress of Iranian Pathology, Nov 2007.
8. Can Breast Cancer Stem cells resist Apoptosis through the regulation of Bcl2? **Madjd z**, Zare Mehrjerdi,.. The 9th annual Congress of Iranian Pathology, Nov 2007.
9. Can complement regulatory proteins use as a target for cancer vaccine in breast cancer patients? **Madjd Z**, Durrant LG, Pinder SE, APPCC, Nov 2007
10. Will Cancer Stem cells use as a new target for cancer treatment? International anatomy Conference, Cell therapy, May 2008
11. Lectures in Pathology CME, Iran University of Medical Sciences, May 2008
12. Cancer Stem cells resist Apoptosis through the regulation of Bcl2. EACR 20, Lyon, France, July 2008

13. Human embryonic stem cell genes OCT4 and NANOG are expressed in breast, brain and thyroid carcinomas compared to testicular carcinoma, 4th international breast cancer conference, Feb 2009, Tehran
14. Prevalence of cancer stem cells and its association with clinical outcome and prognostic factors in breast cancer patients, ncri, Birmenham, Oct 2009, UK
15. Expression of embryonic stem cell markers, OCT4 and NANOG, in breast, thyroid, brain and colorectal carcinomas , ncri, Birmenham, Oct 2009, UK

TEACHING:

Lectures (IUMS*)	Under-graduate students	Medical students, General Pathology	Midwifery Bsc, General Pathology	Public health Bsc, and MPH: non- communicable diseases
	Post-graduate students	Immunology Msc General Pathology	PhD Molecular Medicine PhD and MSc Immunology, parasitology, microbiology: different Immunology courses (Immunochemistry, advanced immunology, Immunotherapy,...)	Immunohistochemistry Methods for: Residents of Pathology PhD Molecular medicine PhD immunology PhD physiology PhD Anatomy
Invited lectures (SBMU**)	Under-graduate students	Pharmacology students, General immunology	Dentist student General immunology	
	Post-graduate students	Immunology, Msc :General Pathology (Total course)	Immunology Msc, Immunochemistry	MPH cancer, Immunology of tumours

*IUMS: Iran University of Medical Sciences

**SBMU: Shahid Beheshti University, MC

PREVIOUS TEACHING EXPERIENCE:

- 1) Supervision of clinical research fellow (surgery) for study of prognostic factors in colorectal tissue microarray, University of Nottingham: 2005
- 2) Supervision of clinical research fellow (gynaecology) for study of prognostic factor in breast tissue array, University of Nottingham: 2005
- 3) Supervision of MSc student (oncology) for making breast tissue array and study of prognostic factors in breast tumours, University of Nottingham: 2005
- 4) Demonstration for BioMed Science students, University of Nottingham: 2004
- 5) Demonstration for pharmacy students, University of Nottingham: 2004

- 6) Supervision of undergraduate students for lab skills in the Department of Clinical Oncology during PhD course: 2001-2004
- 7) Short courses for administrative and health professionals in the Department of School Health: 1999
- 8) Running workshops and short courses for health allies in health centres

Teaching in the following workshops:

- 1) Occupational Cancers, IUMS, 29 Oct 2006
- 2) Immunohistochemistry and Tissue microarray, Annual Pathology Congress, Nov 2006
- 3) How to write your thesis, Nursing PhD students, Nov 2007
- 4) End note , reference manager, in Royan Institue, Nov 2007
- 5) Cancer stem cell workshop, Cellular Molecular Research Centre, Feb 2010

Career Development Fellowship, Post doctorate Scientist, University of Cambridge, Addenbrock's Hospital, MRC Dunn Human Nutrition Unit, Diet and Cancer research group

Outline of study: DNA adducts, differences in gene expression and DNA damage and histochemistry of tumour samples

Post-doctoral Research Fellow

University of Nottingham, City Hospital, Dep. Of Clinical Oncology

Outline of study: Study of immune-surveillance pathway in Breast tumours

Research Experience

A) MD dissertation:

Supervisor: Professor Freidoon Azizi

“Characteristics of thyroid disorders before and after iodized salt consumption in Tehran during 1993-5”.

This study was conducted among patients with thyroid disorders referred to a major Thyroid Referral Centre consisting a population of 12000 patients, that was presented in oral session in 4th International Congress of Endocrine Disorders, Tehran Nov 1996.

B) Description of PhD projects:

Part One: Study of expression of complement regulatory proteins (CIPs) in solid tumours. These antigens (CIPs) are targets for monoclonal antibody therapy (mab), as over-expression of CIPs limits the effectiveness of mab therapy.

Outcome of project: I have examined a number of complement regulatory proteins CD59, CD55 and CD46 on over 600 breast tumours using tissue microarray technology. The results showed that poor prognosis breast tumours lost CD59 and CD55 but still had CD46 to protect them from complement attack. The results of these studies have successfully been published in prestigious Journals. (CD59; J Pathology. August 2003) (CD55, Clinical Cancer Research. April 2004) (CD46; Cancer Immunology Immunotherapy. Sep 2004).

Part 2: Study of the expression of MHC class I molecule and the stress-related molecule MICA and natural killer cells (CD56+) on the same series of breast tissue arrays as above.

Outcome of project: These studies unexpectedly showed up-regulation of HLA ABC and MICA in poor prognosis breast tumours. Several abstracts on these studies have been published and three manuscripts are in preparation.

DETAILS OF RESEARCH EXPERIENCE:

1. Immunohistochemistry (Double staining, analysis and interpretation)

2. Preparing Tissue Microarray

3. Tissue culture

Tissue culture of a variety of cell lines derived from solid tumours including;

- Colorectal cell lines (Colo205, C170, R1D9)
- Breast cell lines (MCF-7, MDA 231, MDA 435, ZR75, and T47D)
- Ovarian cell lines (OAW28, PA1), gastric (MKN45), squamous (A 431), bladder (T24) and osteosarcoma (791T)
- Other cells such as promyelocytic (HL60), monocytic (U937) and promyeloblastic (KG1a)
- HUVEC isolation and culture of HUVEC
- Isolation of activated PBMCs (Peripheral Blood Mononuclear cells) onto histopaque
- Isolation of T cells and T cell culture
- Culture of hybridoma cells

4. Producing monoclonal antibody from hybridoma:

- Design of specific peptide using BLAST search
- Immunisation of mice with specific peptide based on protocol
- Fusion of myeloma cell line NSO with immunised mouse splenocytes
- Culture of Hybridoma and screening by ELISA
- Cloning, Isotype determination and purification of antibody.

5. ELISA:

- Using ELISA to look at expression of complement regulatory proteins (CRPs) on a variety of tumour cell lines including breast (MCF-7, MDA231, MDA435, ZR75, T 47D), colorectal (Colo205, C170, R1D9), gastric (MKN45), bladder (T24), squamous (A431), osteosarcoma (791T) and ovarian (OAW28, PA1)
- HUVEC.

- Screening of hybridoma
- Screening of peptide

6. FACS (Flow cytometry):

- Study of expression of complement regulatory proteins (CRPs), MHC class I on different tumour cell lines including:
 - Bladder and breast cell lines
 - T cells, dendritic cells
 - Leukaemia cell lines; promyelocytic (HL60), promyeloblastic (KG1a) and monocytic (U937) were assessed by FACS analysis

7. SDS polyacrylamide gel electrophoresis (SDS-PAGE) and Western-Blotting:

8. RT-PCR

COURSES

1. Multi Disciplinary Course on Breast Disease, Nottingham Breast Institute 21-23 November 2005.

2. Core of Knowledge (laser/IPL therapy), Laser Training & Education Centre, 5th Oct 2005

3. Teaching Course

- Leicester/ Nottingham MRCPATH Teaching Course (Sep-Dec 2004)
- Prognostic Testing in Cancer, BIR, London, 3 Nov 2004 (5 CPD Credits)

4. Summer school

Cancer Research at Nottingham Summer School and European Association for Cancer Research Symposium, Nottingham, 23-26 July, 2004 (19 CPD Credits)

5. 18th EACR meeting, July 2004, Innsbruck, Austria (24 credit points).

6. Courses in MSc Oncology (University of Nottingham), 2001-2002

These modules have formally been recognised as a course.

1. Diagnostic Pathology of Cancer (15 credits)
2. Techniques in Cellular and Molecular Biology (15 credits)
3. Tumour physiology and immunology (10 credits)

7. Intensive course in English and study Skills

Full-time English Language and Study Skills Course at Centre for English Language Education (CELE), University of Nottingham, for 3 months, September 2000-December 2000.

8. Short term courses (University of Nottingham): 2001-2003

- Introduction to Library Skills, Nottingham Oct 2001
- Study Design/ Experimental Critique, Nottingham Nov 2001
- Statistics, Nottingham, Dec 2001
- Critical Analysis, Nottingham Jan 2002
- Scientific writing, Nottingham, Feb 2002
- Preparing Poster Presentation, Nottingham, March 2002
- PowerPoint for Presentation, Apr 2002
- Scientific Abstract, June 2002
- Excel Intermediate, Nottingham, June 2002
- Further presentation skills, Nov 2001
- Building a bibliography, July 2002
- An introduction to SPSS, May 2002
- Getting More from Microsoft office Applications word, Excel and power point, Nov 2001.
- Getting started with research Design and Statistics, Jan 2002
- Working with Radioactive Substances, March 2002
- Interview workshop, August 2002
- Using Word for Long Documents, December 2002

CONFERENCES

- British Association of Cancer Research, July 2001, Leeds
- British Association of Cancer Research, July 2002, Glasgow
- Progress in vaccine against Cancer (PIVAC), July 2002, Nottingham
- American Association of Cancer Research, March 2003.
- 15th European Immunology Congress (EFIS), 2003.
- American Association of Immunology (AAI), May 2003
- British Association of Cancer Research (BACR), July 2003, Bournemouth
- Federation of European Cancer Societies (FECS), ECCO 12, September 2003, Copenhagen.
- British Society of Immunology (BSI) December 2003, Harrogate.
- American Association of Cancer Research (AACR) March 2004, Orlando
- Cancer Detection and Prevention Strategy, Jan 2004, Nice, France.
- British Cancer Research Meeting (BCRM), Manchester, June 2004.
- European Association of Cancer Research (EACR), July 2004, Innsbruck, Austria.
- NCRI (National Cancer Research Institute), Birmingham, Oct 2005.
- ECCO13 (European Cancer Conference), Paris, Nov 2005.
- International Royan Congress, Sep 2006, Tehran